
Trichomonas Vaginalis (TV) Is there more out there than we think?



Aptima TV NAAT Study
Jane Nicholls & Katy Turner
BASHH Glasgow 2015









Trichomonas Vaginalis (TV)

Is it common?

UK Cases TV (2013)¹ 6475

UK cases Chlamydia 101,179 (16x)

Is it clinically important?

- ✓ Premature labour
- ✓ Increased susceptibility to HIV
- ?? Pelvic inflammatory disease
- ?? Infertility



TV in Primary Care

- Rarely tested for in GP
- Highest rates found in BME population
- Presumed 'negligible' in white population

Bristol situation: what we knew...

- 3% in symptomatic women (Bristol Sexual Health Centre)
- ~0.3% in primary care (local sample 2010)
- Bristol has large Caribbean population 16 % BME¹

Prevalence too low for testing to be cost effective?



Bristol TV study: 4 Groups

Symptomatic GUM
Asymptomatic GUM
Symptomatic GP
Asymptomatic GP

Highest Risk





Q1: Who should we test for TV?



?? True TV Prevalence in Clinic & GP

using leftover samples from dual NAAT tests

?? Aptima® TVNAAT, vs wet prep and culture (92%, 38% and 88% sensitivity respectively¹)



Q2: Is it worth it?



?? Extra Cost:

cost per additional positive

?? Cost Effectiveness:

targeted or universal TV testing strategy




4 Study Groups – female patients

	Group 1 GUM Symptomatic S-GUM	Group 2 GUM Asymptomatic A-GUM	Group 3 GP Symptomatic S-GP	Group 4 GP Asymptomatic A-GP	
Symptoms	Discharge, irritation, pain	Nil or Nil revealed	Vaginal discharge selected on ICE	STI risk selected on ICE	
Eligibility	All women attending GUM		All women for whom GP requested chlamydia/gonorrhoea test		
Consent	Written	Posters	Opt-out consent using ICE + Posters		
Samples	Self- & physician- Remnant sample	collected swabs No extra needed	4 clicks!		
Exclusions	<18, pregnant				
Patient data	Age, ethnicity, postcode		Age, GP practice location		
Timeframe	21 months, May 2013 - Jan 2015		Total Sample n=9240		



Opt out consent request (ICE)




Summary results – All groups

S-GUM	A-GUM	S-GP	A-GP
N = 543	1593	3512	3592




TV NAAT Positivity Rate %







TV Detection NAAT vs Traditional



STI Positivity Rate %




Age + STI Positivity Rate %






Age + STI Positivity Rate %







Ethnicity + TV Positivity Rate %




Black Caribbean Ethnicity - Bristol



Black Caribbean Ethnicity - Weston



High TV rates: link to deprivation?





6 practices with highest TV rates

Positivity >3% + >130 patients tested

Practices N > 130 pt

Positives / tested

% BME

Dep Index



Deprivation Index Bristol average IMD = 25.2



Should I care about TV in 1°Care? not my problem

- Total cases diagnosed in GUM 54
- Total cases diagnosed in GP 136
- GUM + GP populations overlap





Main Study Findings

- Substantial TV rate in GUM women
 4.8% sympt. 1.8% asympt. 2.5% overall
- TV rate <u>much higher</u> in GP than expected
 2.7% sympt. 1.1% asympt. 1.9% overall

```
GUM GP GUM GP Asympt Asympt
```

- Some findings consistent with known epidemiology
 Age >25, Black Caribbean ethnicity
- TV rate varies greatly by practice:
 Deprivation is an independent risk
 Any other "Mystery" factors ??



Question: Is it worth it?



?? Extra Cost:

cost per additional positive



?? Cost Effectiveness:

targeted or universal TV testing strategy

Katy Turner PhD, University of Bristol



Considerations

- Clinical problem
- Prevalence
- Cost of testing and management (£, £/positive)
- Benefit of diagnosis & treatment (QALY)
- Transmission dynamics
- Cost-effectiveness (£/QALY)



Considerations

Clinical problem

V

Prevalence



Cost of testing & management (£, £/positive)



Benefit of diagnosis & treatment (QALY)



Transmission dynamics



Cost-effectiveness (£/QALY)






Methods


- Calculate COSts associated with TV testing
- Compare existing testing with different testing scenarios using TV NAAT
- Calculate total cost of each scenario
- Calculate cost per positive test



Current testing strategy (TV Micro/Cult)



New testing strategy (TV NAAT)



Costs

TV test

Added to CT/GC NAAT = £7.62

Standalone = £15.19

Microscopy + Culture = £7.93

Sexual health screen

Asymptomatic £79.77* Symptomatic £99.38*




Testing scenarios

- 1. All samples sent for STI testing
- 2. Symptomatic samples (GUM/GP)
- 3. Targeted high prevalence GPs
- 4. Combination




Cost of universal TV NAAT test






Adjusted total cost






Cost per additional positive





Testing scenarios





Primary Care TV Testing


Test all patients with TV NAAT, stop doing microbiology testing

Equitable

High cost

Loss of lab capability

Prevalence affects Cost* per TV +





Future Plans for Bristol... GUM

- TV NAATs for symptomatic women
- TV NAATs for asymptomatics too expensive ?
- Target high risk patients: age + ethnicity?
- NAAT urine for male contacts of TV+ women?

GP

- TV NAATs for symptomatic women
- How to identify other high risk General Practices?
 - further study!



Conclusions

- First UK study in primary care N= 9240
- High TV positivity found (2.7% GP symptoms+)

Targeting?

- Testing symptoms+ is most cost effective
- Ethnicity alone misses >65% of cases
- Deprivation is independent risk factor
- Is there another Mystery Factor?





Acknowledgements





PHE Virology Lab Bristol

- Peter Muir
- Paul North
- Ralph Ferguson
- The NAAT team

Dept. of Social & Community Medicine

- Paddy Horner
- Margaret May
- John Macleod
- Suzanne Ingle



GPs & practice nurses Bristol, Weston & Bath

